Cite

HARVARD Citation

    Xiang, M. et al. (2021). Anlotinib Combined with S‐1 in Third‐ or Later‐Line Stage IV Non‐Small Cell Lung Cancer Treatment: A Phase II Clinical Trial. Oncologist. pp. e2130-e2135. [Online]. 
  
Back to record